ResBiotic, a biotech startup based in Birmingham, has secured $4.5 million in seed funding as it launches its first consumer health product for the treatment of respiratory conditions.
The seed round brings the total funding raised by the startup to $7.5 million, which boosted the development of its resB® Lung Support solution, an oral supplement that uses probiotics to improve respiratory health. The product was developed by the recently founded subsidiary Alveolus Bio. Dr. C. Vivek Lal MD FAAP, the founder of ResBiotic and Alveolus, said in this regard:
“Considering the therapeutic potential of microbiome-based products for lung health, it was essential that we create a subsidiary company to support a pharmaceutical pipeline separate from our consumer nutrition division. Our pharmaceutical arm is developing biotherapeutics for specific chronic respiratory conditions. Meanwhile, the consumer group remains focused on science-backed proactive products that anyone concerned about their lung health can use and benefit from today.”
Founded in 2018, ResBiotic was the result of more than a decade of research at the University of Alabama. While the startup originally focused on the development of new therapeutic approaches for the treatment of conditions caused by dysbiosis. With the data recompiled during all those years around the respiratory system and the effects of microbiomes on it, the startup set itself to the mission of revolutionizing the respiratory care landscape.
By developing new therapeutic solutions, ResBiotic could help improve the quality of life of more than 100 million Americans affected by respiratory diseases. According to the Associated Press, access to respiratory specialists has decreased by 7% despite the demand for them increasing by 25%.
This, in addition to the COVID19 pandemic’s effects, has prompted governments and companies to invest heavily in healthcare research, which has allowed startups like ResBiotic to experience rapid growth. Now, the startup is looking to sustain this growth by allocating additional resources to R&D and marketing efforts.